X4 Pharmaceuticals, Inc. (XFOR), on Wednesday, announced that Chief Medical Officer Christophe Arbet-Engels has resigned for personal reasons and Chief Operating Officer Mary DiBiase will leave the company. The company has appointed President John Volpone appointed Chief Operating Officer.
The company said that Christophe Arbet-Engels will continue to assist during the transition period.
Chief Legal & Compliance Officer Natasha Thoren and Chief Commercial Officer Mark Baldry are also leaving the company.
The company said the move is a strategic restructuring to sharpen operational focus and align resources with its long-term goal of completing the 4WARD Phase 3 trial in chronic neutropenia.
The plan includes a 50% workforce reduction, expected to deliver annualized cost savings of about $13 million.
Executive Chairman Dr. Adam Craig will lead clinical development.
In the pre-market trading, X4 Pharmaceuticals is 0.93% lesser at $3.1800 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.